Silo Pharma Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a significant step forward in the development of its PTSD drug, SPC-15. The company has initiated a 7-day safety and toxicology study at Frontage Laboratories, a global contract research organization. This study, requested by the FDA, aims to gather crucial data to support Silo's investigational new drug $(IND.AU)$ application for SPC-15, an intranasal prophylactic treatment targeting the multi-billion-dollar PTSD market. The company remains on track to submit an FDA application this year, with plans to proceed to a first-in-human Phase 1 clinical trial upon approval. Silo has an exclusive global license from Columbia University for the development and commercialization of SPC-15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.